MacroGenics gets $15M from Gilead; Zenas, Bristol Myers sign licensing deal in Asia-Pacific
MacroGenics is set to receive a $15 million milestone payment from Gilead, which is using the company’s two bispecific antibody platforms …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
